Peter K Harris
Overview
Explore the profile of Peter K Harris including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chauhan P, Alahi I, Sinha S, Ledet E, Mueller R, Linford J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):151-163.
PMID: 39177583
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning...
2.
Chauhan P, Alahi I, Sinha S, Shiang A, Mueller R, Webster J, et al.
medRxiv
. 2023 Dec;
PMID: 38077092
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms are ill-understood. Here, we...
3.
Earland N, Semenkovich N, Ramirez R, Gerndt S, Harris P, Gu Z, et al.
Clin Cancer Res
. 2023 Nov;
30(7):1409-1421.
PMID: 37939112
Purpose: Our goal was to demonstrate that lymphatic drainage fluid (lymph) has improved sensitivity in quantifying postoperative minimal residual disease (MRD) in locally advanced human papillomavirus (HPV)-associated oropharyngeal squamous cell...
4.
Storrs E, Chati P, Usmani A, Sloan I, Krasnick B, Babbra R, et al.
NPJ Precis Oncol
. 2023 Oct;
7(1):105.
PMID: 37857854
Numerous cell states are known to comprise the pancreatic ductal adenocarcinoma (PDAC) tumor microenvironment (TME). However, the developmental stemness and co-occurrence of these cell states remain poorly defined. Here, we...
5.
Webster J, Dang H, Chauhan P, Feng W, Shiang A, Harris P, et al.
Bioinformatics
. 2023 Aug;
39(8).
PMID: 37549060
Motivation: Detection of genomic alterations in circulating tumor DNA (ctDNA) is currently used for active clinical monitoring of cancer progression and treatment response. While methods for analysis of small mutations...
6.
Wang Y, Morrissey J, Gupta P, Chauhan P, Pachynski R, Harris P, et al.
ACS Appl Mater Interfaces
. 2023 Apr;
15(15):18598-18607.
PMID: 37015072
Traditional cold chain systems of collection, transportation, and storage of biofluid specimens for eventual analysis pose a huge financial and environmental burden. These systems are impractical in pre-hospital and resource-limited...
7.
Chauhan P, Shiang A, Alahi I, Sundby R, Feng W, Gungoren B, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):6.
PMID: 36658307
Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease (MRD) detection in bladder cancer patients. To remedy this problem, we focused on the biofluid most proximal to the...
8.
Manjunath Y, Suvilesh K, Mitchem J, Avella Patino D, Kimchi E, Staveley-OCarroll K, et al.
JCO Precis Oncol
. 2022 Apr;
6:e2100378.
PMID: 35417204
Purpose: Low-dose computed tomography (LDCT) screening of high-risk patients decreases lung cancer-related mortality. However, high false-positive rates associated with LDCT result in unnecessary interventions. To distinguish non-small-cell lung cancer (NSCLC)...
9.
Lozano A, Chaudhuri A, Nene A, Bacchiocchi A, Earland N, Vesely M, et al.
Nat Med
. 2022 Jan;
28(2):353-362.
PMID: 35027754
Severe immune-related adverse events (irAEs) occur in up to 60% of patients with melanoma treated with immune checkpoint inhibitors (ICIs). However, it is unknown whether a common baseline immunological state...
10.
Chauhan P, Chen K, Babbra R, Feng W, Pejovic N, Nallicheri A, et al.
PLoS Med
. 2021 Dec;
18(12):e1003876.
PMID: 34905549
[This corrects the article DOI: 10.1371/journal.pmed.1003732.].